Evidence map›Paper›PMID 40781159›Full record

ArticleOncogene2025

Retraction Note: Targeting STING elicits GSDMD-dependent pyroptosis and boosts anti-tumor immunity in renal cell carcinoma.

Shengpan Wu, Baojun Wang, Hongzhao Li, Hanfeng Wang, Songliang Du, Xing Huang, Yang Fan, Yu Gao, Liangyou Gu, Qingbo Huang and 4 more

Abstract readRetraction Notice
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Shengpan Wu *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Baojun Wang *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Hongzhao Li *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Hanfeng WangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Songliang DuDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.ORCID http://orcid.org/0000-0002-8156-0792
Xing HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Yang FanDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Yu GaoDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Liangyou GuDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.
Qingbo HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China.ORCID http://orcid.org/0000-0003-2894-0187
Jianjun ChenSchool of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou, 510515, China.
Xu ZhangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China. xzhang301@163.com.ORCID http://orcid.org/0000-0002-6908-6768
Yan HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China. dr.huangyan301@foxmail.com.
Xin MaDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, 100853, Beijing, China. mxin301@126.com.ORCID http://orcid.org/0000-0001-8257-4670

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40781159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.